Key Highlights
- DeepCure selects DC-9476, a novel BRD inhibitor, as its first development candidate.
- DC-9476 targets multiple autoimmune disease pathways with high selectivity for Brd4 BD2.
- Promising preclinical results in rheumatoid arthritis and Still’s disease.
- Excellent safety profile compared to earlier BRD inhibitors.
- Discovered using DeepCure’s proprietary AI platform.
Source: Business Wire
Notable Quotes
- “New therapeutics such as DC-9476 that have a novel mechanism to address simultaneously multiple pathways while also having an excellent safety profile, are extremely promising for the field.” — Professor Francesco Del Galdo, M.D., Ph.D., at University of Leeds
- “We’re excited to announce our first AI-generated candidate, which we plan to advance into clinical trials next year. This validates our generative AI and physics-based drug discovery engine.” — Kfir Schreiber, CEO & Co-Founder at DeepCure
SoHC's Take
DeepCure’s advancement of DC-9476 into clinical trials marks a significant milestone in the field of drug discovery, particularly for autoimmune diseases. The use of AI to identify and develop this candidate underscores the transformative potential of technology in medicine. By targeting multiple pathways simultaneously while maintaining a strong safety profile, DC-9476 could offer a more effective treatment option for patients with complex autoimmune conditions. This development not only validates DeepCure’s innovative AI platform but also sets the stage for future breakthroughs in therapeutics.
